trial

Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Disorders With Proven Dysimmunity.

NCTId NCT05946486
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 174 (estimated)
Sponsored by University Hospital, Bordeaux
Primary completion 2026-01-15
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
174 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2023-10-15
Primary completion
2026-01-15
Eligibility
ALL · 6 Years

Interventions & indications

Drugs
immunomodulatory treatment by rituximab

Sponsors

University Hospital, BordeauxLead Sponsor

Investigators

1
Frédéric VILLEGA, MD, PhDPrincipal Investigator

Sites

9 total
Bordeaux, FranceBordeaux, FranceBron, FranceClermont-Ferrand, FranceColombes, FranceCréteil, FranceLe Kremlin-Bicêtre, FranceMontpellier, FranceStrasbourg, France

Linked catalysts

1
Evaluation of the Efficacy of Immunomodulatory Therapy in Case of Psychiatric Di — primary completion2026-01-15

Facts & assertions

4 sourced
Enrollment
174
Phase
PHASE3
Primary Completion Date
2026-01-15
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
immunomodulatory treatment by rituximab
drug
lead_sponsor
University Hospital, Bordeaux
company
indication
Psychotic Disorders
indication
Mental Disorder
indication
Mental Disorders
indication
investigator
Frédéric VILLEGA, MD, PhD
person